Capricor Therapeutics Company Profile (OTCMKTS:CAPR)

About Capricor Therapeutics (OTCMKTS:CAPR)

Capricor Therapeutics logoCapricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:CAPR
  • CUSIP: N/A
  • Web: capricor.com
Capitalization:
  • Market Cap: $58.27 million
  • Outstanding Shares: 23,496,000
Average Prices:
  • 50 Day Moving Avg: $1.89
  • 200 Day Moving Avg: $1.64
  • 52 Week Range: $0.63 - $4.25
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.26
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.53 million
  • Price / Sales: 16.51
  • Book Value: ($0.29) per share
  • Price / Book: -8.55
Profitability:
  • EBITDA: ($14,960,000.00)
  • Net Margins: -348.45%
  • Return on Assets: -98.47%
Misc:
  • Average Volume: 2.94 million shs.
  • Short Ratio: 0.09
 

Frequently Asked Questions for Capricor Therapeutics (OTCMKTS:CAPR)

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the OTCMKTS under the ticker symbol "CAPR."

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (OTCMKTS:CAPR) announced its quarterly earnings data on Thursday, August, 10th. The company reported ($0.16) EPS for the quarter, beating the Zacks' consensus estimate of ($0.18) by $0.02. The business earned $1 million during the quarter, compared to analysts' expectations of $1.10 million. View Capricor Therapeutics' Earnings History.

When will Capricor Therapeutics make its next earnings announcement?

Capricor Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Capricor Therapeutics.

Where is Capricor Therapeutics' stock going? Where will Capricor Therapeutics' stock price be in 2017?

3 analysts have issued 12-month target prices for Capricor Therapeutics' shares. Their predictions range from $2.15 to $12.00. On average, they expect Capricor Therapeutics' stock price to reach $6.88 in the next year. View Analyst Ratings for Capricor Therapeutics.

Who are some of Capricor Therapeutics' key competitors?

Who are Capricor Therapeutics' key executives?

Capricor Therapeutics' management team includes the folowing people:

  • Frank I. Litvack M.D., Independent Executive Chairman of the Board
  • Linda Marban Ph.D., President, Chief Executive Officer, Director
  • Leland J. Gershell M.D. Ph.D., Chief Financial Officer, Principal Financial Officer
  • Karen G. Krasney J.D., Executive Vice President, General Counsel
  • Anthony Bergmann, Principal Accounting Officer, Vice President - Finance
  • Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development
  • Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
  • Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
  • Rachel Smith Ph.D., Vice President - Research & Development
  • Deborah Ascheim M.D., Chief Medical Officer

How do I buy Capricor Therapeutics stock?

Shares of Capricor Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Capricor Therapeutics' stock price today?

One share of Capricor Therapeutics stock can currently be purchased for approximately $2.48.


MarketBeat Community Rating for Capricor Therapeutics (OTCMKTS CAPR)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  88 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  196
MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Capricor Therapeutics (OTCMKTS:CAPR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.88
Consensus Price Target History for Capricor Therapeutics (OTCMKTS:CAPR)
Price Target History for Capricor Therapeutics (OTCMKTS:CAPR)
Analysts' Ratings History for Capricor Therapeutics (OTCMKTS:CAPR)
Show:
DateFirmActionRatingPrice TargetDetails
9/15/2017HC WainwrightBoost Price TargetBuy -> Buy$2.15 -> $6.50View Rating Details
7/22/2017Rodman & RenshawReiterated RatingBuy$2.15View Rating Details
10/20/2016Roth CapitalSet Price TargetBuy$12.00View Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Capricor Therapeutics (OTCMKTS:CAPR)
Earnings by Quarter for Capricor Therapeutics (OTCMKTS:CAPR)
Earnings History by Quarter for Capricor Therapeutics (OTCMKTS CAPR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.19)N/AView Earnings Details
8/10/2017Q2 2017($0.18)($0.16)$1.10 million$1.00 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.15)($0.17)$0.87 million$0.88 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.30)($0.14)$1.05 million$0.91 millionViewN/AView Earnings Details
11/10/2016Q316($0.27)($0.29)$1.12 million$0.75 millionViewN/AView Earnings Details
8/15/2016Q2($0.24)($0.26)$1.22 million$1.13 millionViewListenView Earnings Details
5/12/2016Q116($0.19)($0.26)$1.10 million$1.22 millionViewListenView Earnings Details
3/17/2016Q415($0.19)($0.21)$1.10 million$1.12 millionViewN/AView Earnings Details
11/12/2015Q315($0.26)($0.18)$1.10 million$1.32 millionViewN/AView Earnings Details
8/13/2015Q215($0.26)($0.19)$1.10 million$1.29 millionViewN/AView Earnings Details
5/12/2015Q1 2015($0.14)($0.23)$1.10 million$1.79 millionViewN/AView Earnings Details
3/18/2015Q4 2014($0.14)($0.16)$1.30 million$1.40 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.22)($0.13)$1.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Capricor Therapeutics (OTCMKTS:CAPR)
Current Year EPS Consensus Estimate: $-0.70 EPS
Next Year EPS Consensus Estimate: $-0.76 EPS

Dividends

Dividend History for Capricor Therapeutics (OTCMKTS:CAPR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Capricor Therapeutics (OTCMKTS:CAPR)
Insider Trades by Quarter for Capricor Therapeutics (OTCMKTS:CAPR)
Institutional Ownership by Quarter for Capricor Therapeutics (OTCMKTS:CAPR)
Insider Trades by Quarter for Capricor Therapeutics (OTCMKTS:CAPR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/9/2017Louis ManzoDirectorBuy10,000$3.10$31,000.00View SEC Filing  
5/9/2017Sinai Medical Center CedarsMajor ShareholderBuy1,145,161$3.10$3,549,999.10View SEC Filing  
9/21/2016Sinai Medical Center CedarsMajor ShareholderBuy312,500$3.20$1,000,000.00View SEC Filing  
3/16/2016Anthony BergmannVPBuy2,030$2.40$4,872.00View SEC Filing  
3/16/2016Karen KrasneyEVPBuy4,060$2.40$9,744.00View SEC Filing  
3/16/2016Leland GershellCFOBuy2,100$2.40$5,040.00View SEC Filing  
3/16/2016Linda MarbanCEOBuy10,152$2.40$24,364.80View SEC Filing  
3/16/2016Louis J GrasmickDirectorBuy91,369$2.40$219,285.60View SEC Filing  
3/16/2016Sinai Medical Center CedarsMajor ShareholderBuy416,666$2.40$999,998.40View SEC Filing  
8/20/2015Louis J. GrasmickDirectorBuy11,900$4.11$48,909.00View SEC Filing  
8/19/2015Eduardo Marbanmajor shareholderBuy18,400$4.36$80,224.00View SEC Filing  
1/21/2015Joshua A KazamDirectorBuy7,096$3.52$24,977.92View SEC Filing  
1/21/2015Sinai Medical Center CedarsMajor ShareholderBuy851,546$3.52$2,997,441.92View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Capricor Therapeutics (OTCMKTS:CAPR)
Latest Headlines for Capricor Therapeutics (OTCMKTS:CAPR)
Source:
DateHeadline
seekingalpha.com logoCapricor Therapeutics: 12-Month Data Could Push Shares Higher - Seeking Alpha
seekingalpha.com - October 18 at 4:15 AM
finance.yahoo.com logoETFs with exposure to Capricor Therapeutics, Inc. : October 10, 2017
finance.yahoo.com - October 10 at 6:09 PM
streetinsider.com logoCapricor Therapeutics (CAPR) Says Intravenous Administration of CAP-1002 Shown to be Effective in Preclinical Models of DMD
www.streetinsider.com - October 8 at 4:17 PM
reuters.com logoBRIEF-Capricor Therapeutics presents positive six-month results in duchenne muscular dystrophy at WMS International Congress
www.reuters.com - October 4 at 3:35 PM
seekingalpha.com logoCapricor's lead candidate CAP-1002 shows positive effect on heart function in young men with advanced DMD; shares ... - Seeking Alpha
seekingalpha.com - October 4 at 12:37 PM
prnewswire.com logoCapricor Therapeutics Presents Positive Six-Month Results in ... - PR Newswire (press release)
www.prnewswire.com - October 4 at 12:37 PM
finance.yahoo.com logoCapricor Therapeutics Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at World Muscle Society International Congress
finance.yahoo.com - October 4 at 12:37 PM
nasdaq.com logoCapricor Therapeutics (CAPR) Looks Good: Stock Adds 13.9% in Session - Nasdaq
www.nasdaq.com - October 3 at 4:46 PM
finance.yahoo.com logoCapricor Therapeutics (CAPR) Looks Good: Stock Adds 13.9% in Session
finance.yahoo.com - October 3 at 4:46 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Skyline Medical and Capricor
finance.yahoo.com - October 2 at 3:18 PM
streetinsider.com logoCapricor Therapeutics (CAPR) Announces Naming of Principal Investigator for Program in DMD
www.streetinsider.com - September 27 at 5:41 PM
prnewswire.com logoCapricor Therapeutics Advances Clinical Development Program in Duchenne Muscular Dystrophy with Naming of ... - PR Newswire (press release)
www.prnewswire.com - September 26 at 8:32 AM
finance.yahoo.com logoCapricor Therapeutics Advances Clinical Development Program in Duchenne Muscular Dystrophy with Naming of Principal Investigator
finance.yahoo.com - September 26 at 8:32 AM
finance.yahoo.com logoETFs with exposure to Capricor Therapeutics, Inc. : September 22, 2017
finance.yahoo.com - September 22 at 3:55 PM
finance.yahoo.com logoCapricor Therapeutics, Inc. :CAPR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
finance.yahoo.com - September 20 at 5:43 PM
finance.yahoo.com logoCapricor Therapeutics, Inc. :CAPR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
finance.yahoo.com - September 20 at 5:43 PM
nasdaq.com logoCAPR Is Hot, VBLT In Rally Mode, MYOK's Data Heartening, MediWound Bleeds
www.nasdaq.com - September 19 at 10:03 PM
finance.yahoo.com logoCapricor Therapeutics to Present Six-Month Results from the Randomized HOPE Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society
finance.yahoo.com - September 18 at 5:15 PM
finance.yahoo.com logoCapricor Therapeutics to Present Six-Month Results from the Randomized HOPE Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society
finance.yahoo.com - September 18 at 5:15 PM
americanbankingnews.com logoCapricor Therapeutics Inc (CAPR) Given New $6.50 Price Target at HC Wainwright
www.americanbankingnews.com - September 15 at 8:00 PM
americanbankingnews.com logoCapricor Therapeutics Inc (CAPR) Given a $2.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - August 14 at 11:40 AM
finance.yahoo.com logoETFs with exposure to Capricor Therapeutics, Inc. : August 11, 2017
finance.yahoo.com - August 11 at 5:20 PM
americanbankingnews.com logoCapricor Therapeutics Inc (CAPR) Announces Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - August 11 at 1:04 PM
reuters.com logoBRIEF-Capricor Therapeutics Q2 loss per share $0.16
www.reuters.com - August 11 at 4:09 AM
finance.yahoo.com logoCapricor Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 10 at 6:05 PM
finance.yahoo.com logoCapricor reports 2Q loss
finance.yahoo.com - August 10 at 6:05 PM
bizjournals.com logoBreakfast Technical Briefing on Biotech Stocks -- CytRx, Aeterna Zentaris, Capricor Therapeutics, and Cymabay Therapeutics
www.bizjournals.com - August 8 at 9:41 PM
americanbankingnews.com logoCapricor Therapeutics Inc (OTCMKTS:CAPR) to Release Earnings on Monday
www.americanbankingnews.com - August 7 at 7:50 AM
finance.yahoo.com logo10 Pieces Of Advice Every Penny Stock Trader Should Know
finance.yahoo.com - August 6 at 9:20 PM
finance.yahoo.com logoCapricor Therapeutics Second Quarter 2017 Update Webcast and Conference Call Scheduled for Thursday, August 10
finance.yahoo.com - August 3 at 6:26 PM
finance.yahoo.com logoETFs with exposure to Capricor Therapeutics, Inc. : August 1, 2017
finance.yahoo.com - August 1 at 5:44 PM
finance.yahoo.com logoETFs with exposure to Capricor Therapeutics, Inc. : August 1, 2017
finance.yahoo.com - August 1 at 5:44 PM
streetinsider.com logoCapricor Therapeutics (CAPR) Announces Results of FDA Meeting on Intravenous CAP-1002 for DMD
www.streetinsider.com - July 28 at 6:25 PM
finance.yahoo.com logoWe Spoke With The Experts, And Learned The Secrets Behind Beating The Penny Stock Market
finance.yahoo.com - July 28 at 6:24 PM
streetinsider.com logoPre-Open Stock Movers 07/27: (CAPR) (SHOR) (FB) Higher; (CUR) (AZN) (CYH) Lower (more...)
www.streetinsider.com - July 27 at 4:19 PM
baystreet.ca logoInvestors Cheer FDA Meeting on Capricor Cell Therapy for Duchenne Muscular Dystrophy
www.baystreet.ca - July 27 at 4:19 PM
finance.yahoo.com logoCapricor Announces Results of FDA Meeting on Intravenous CAP-1002 for Duchenne Muscular Dystrophy
finance.yahoo.com - July 27 at 4:19 PM
americanbankingnews.com logoCapricor Therapeutics Inc (CAPR) Stock Rating Reaffirmed by Rodman & Renshaw
www.americanbankingnews.com - July 22 at 12:18 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Capricor Therapeutics and Immunocellular Therapeutics
finance.yahoo.com - July 19 at 6:07 PM
finance.yahoo.com logoRodman and Renshaw Sings the Praises of Capricor Therapeutics, Inc. (CAPR); Here’s Why
finance.yahoo.com - July 19 at 6:07 PM
streetinsider.com logoCapricor Therapeutics (CAPR) Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with DMD
www.streetinsider.com - July 18 at 6:25 PM
finance.yahoo.com logoCapricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystrophy
finance.yahoo.com - July 18 at 6:25 PM
finance.yahoo.com logoTuesday’s Wall Street News: Netflix, Inc. (NFLX), Capricor Therapeutics Inc (CAPR), Moleculin Biotech Inc (MBRX)
finance.yahoo.com - July 18 at 6:25 PM
americanbankingnews.com logoCapricor Therapeutics Inc (OTCMKTS:CAPR) Given a $2.00 Price Target at HC Wainwright
www.americanbankingnews.com - July 18 at 4:17 PM
finance.yahoo.com logoFeatured Company News - Janssen Biotech Backs Out of Exclusive Licence Agreement for Development and Commercialization of Capricor's Lead Candidate CAP-1002
finance.yahoo.com - July 10 at 4:55 PM
reuters.com logoBRIEF-Capricor Therapeutics files for resale of up to 1.2 mln shares of co's common stock by the selling stockholders - SEC Filing
www.reuters.com - July 8 at 9:31 AM
reuters.com logoBRIEF-Capricor Therapeutics retains full rights to CAP-1002 as Janssen Biotech decides not to exercise option
www.reuters.com - July 6 at 11:14 PM
finance.yahoo.com logoCapricor Therapeutics Retains Full Rights to CAP-1002 as Janssen Biotech, Inc. Decides Not to Exercise Option
finance.yahoo.com - July 6 at 11:14 PM
reuters.com logoBRIEF-Capricor unit enters into amendment to CIRM notice of loan award
www.reuters.com - June 13 at 8:45 PM
seekingalpha.com logoCapricor Therapeutics (CAPR) Presents At 7th Annual LD Micro Invitational Conference
seekingalpha.com - June 7 at 4:04 PM

Social

Chart

Capricor Therapeutics (CAPR) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.